Aptevo Therapeutics (APVO) Cash & Equivalents (2015 - 2026)

Aptevo Therapeutics has reported Cash & Equivalents for 12 years, with the latest figure at $14.5 million in Q1 2026.

• Quarterly Cash & Equivalents rose 579.06% year-over-year to $14.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.5 million (up 579.06% YoY) and the FY2025 annual result came in at $21.6 million, up 1730.57% from the prior year.
• Cash & Equivalents slipped to $14.5 million in Q1 2026 per APVO's latest filing, from $21.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $36.2 million in Q1 2022 and troughed at $1.1 million in Q4 2022.
• A 5-year average of $13.4 million and a median of $10.2 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents slumped 97.7% in 2022, then jumped 1730.57% in 2025.
• Over 5 years, Cash & Equivalents stood at $1.1 million in 2022, then surged by 1485.74% to $16.9 million in 2023, then slumped by 93.01% to $1.2 million in 2024, then surged by 1730.57% to $21.6 million in 2025, then sank by 32.81% to $14.5 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $14.5 million, $21.6 million, and $3.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.